Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 1
2006 1
2007 1
2008 3
2009 2
2010 1
2022 4
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Safety, effectiveness, and cost-effectiveness of immediate versus delayed sequential bilateral cataract surgery in the Netherlands (BICAT-NL study): a multicentre, non-inferiority, randomised controlled trial.
Spekreijse L, Simons R, Winkens B, van den Biggelaar F, Dirksen C, Bartels M, de Crom R, Goslings O, Joosse M, Kasanardjo J, Lansink P, Ponsioen T, Reus N, Schouten J, Nuijts R. Spekreijse L, et al. Among authors: ponsioen t. Lancet. 2023 Jun 10;401(10392):1951-1962. doi: 10.1016/S0140-6736(23)00525-1. Epub 2023 May 15. Lancet. 2023. PMID: 37201546 Clinical Trial.
Central Retinal Vein Occlusion 36-Month Outcomes with Anti-VEGF: The Fight Retinal Blindness! Registry.
Hunt A, Nguyen V, Bhandari S, Ponsioen T, McAllister IL, Arnold J, Young S, Gabrielle PH, Mehta H, O' Toole L, Alforja S, Zarranz-Ventura J, Barthelmes D, Gillies M. Hunt A, et al. Among authors: ponsioen t. Ophthalmol Retina. 2023 Apr;7(4):338-345. doi: 10.1016/j.oret.2022.11.001. Epub 2022 Nov 9. Ophthalmol Retina. 2023. PMID: 36371040 Free article.
Incidence, Risk Factors, and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-VEGF for Retinal Diseases: Data from the Fight Retinal Blindness! Registry.
Gabrielle PH, Nguyen V, Arnould L, Viola F, Zarranz-Ventura J, Barthelmes D, Creuzot-Garcher C, Gillies M; Fight Retinal Blindness! Study Group. Gabrielle PH, et al. Ophthalmol Retina. 2022 Nov;6(11):1044-1053. doi: 10.1016/j.oret.2022.05.008. Epub 2022 May 16. Ophthalmol Retina. 2022. PMID: 35589075 Free article.
Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry.
Hunt AR, Nguyen V, Arnold JJ, McAllister IL, Mehta H, Invernizzi A, Ponsioen T, Gabrielle PH, O'Toole L, Kusenda P, Alforja S, Barthelmes D, Gillies MC. Hunt AR, et al. Among authors: ponsioen t. Br J Ophthalmol. 2023 Jun;107(6):842-848. doi: 10.1136/bjophthalmol-2021-320482. Epub 2022 Jan 25. Br J Ophthalmol. 2023. PMID: 35078771 Free PMC article.
Collagen distribution in the human vitreoretinal interface.
Ponsioen TL, van Luyn MJ, van der Worp RJ, van Meurs JC, Hooymans JM, Los LI. Ponsioen TL, et al. Invest Ophthalmol Vis Sci. 2008 Sep;49(9):4089-95. doi: 10.1167/iovs.07-1456. Epub 2008 Apr 30. Invest Ophthalmol Vis Sci. 2008. PMID: 18450587 Free article.
Three-Year Outcomes of VEGF Inhibitors in Naive Branch Retinal Vein Occlusion: Fight Retinal Blindness!
Alforja S, Hunt A, Nguyen V, O'Toole L, Gabrielle PH, Invernizzi A, Mehta H, Ponsioen TL, Squirrell D, Casaroli-Marano RP, Barthelmes D, Gillies MC, Zarranz-Ventura J; Fight Retinal Blindness (FRB) users group. Alforja S, et al. Among authors: ponsioen tl. Ophthalmol Retina. 2024 Apr 18:S2468-6530(24)00189-1. doi: 10.1016/j.oret.2024.04.014. Online ahead of print. Ophthalmol Retina. 2024. PMID: 38641007
14 results